All five products were identified during an examination of international mail shipments, and laboratory analyses later confirmed that they contain various harmful and hidden drug ingredients.
Citrus’ Fit & Adelgazantes R-II
The FDA is warning consumers not to use or purchase Citrus’ Fit and Adelgazantes R-II, which are both promoted for weight loss. The FDA’s lab analyses identified and confirmed that both products contain sibutramine.
Sibutramine, a controlled substance, was removed from the market for safety reasons in October 2010. According to the FDA’s notice, “sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.” Furthermore, the product could also have life-threatening interactions with other medications being taken by consumers.
In addition to sibutramine, FDA’s analysis of Citrus’ Fit also determined that the product contains desmethylsibutramine, a substance similar in structure to sibutramine, thus furthering the Agency’s safety concerns associated with the product’s use.
Boss-Rhino Gold X-tra Strength, Anaconda Strong Formula, & De Guo Hei Bei (徳国黑倍)
During FDA’s lab analyses of Boss-Rhino Gold X-tra Strength, Anaconda Strong Formula, and De Guo Hei Bei (徳国黑倍), the Agency found that the products contain sildenafil. Sildenafil is the active ingredient in Viagra, the FDA-approved drug indicated for the treatment of erectile dysfunction (ED). Although sildenafil is approved by FDA in some products, the Agency notes that it “may interact with nitrates found in some prescription drugs, such as nitroglycerin, and may lower blood pressure to dangerous levels.” Nitrates are often taken by men with diabetes, high blood pressure, high cholesterol, or heart disease.
Are you in the process of developing a dietary supplement? Do you have a supplement that you’re looking to verify is compliant with all FDA regulations? We can help you achieve a successful interaction with FDA. To learn more about our services and how we can help you, contact us today.
Senator: FDA’s Backlog of ANDAs is Causing “Harm” to Consumers
On September 28, 2015, Sen. David Vitter (R-LA) sent a letter to FDA’s Acting Commissioner, Stephen Ostroff, MD, in which he stated various concerns regarding an extensive backlog of Abbreviated New...